Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Getinge ABCHIX:GETIBS 73 5-Year Yield-on-Cost % is 5.45 as of Jul. 27, 2026, which is 19% above its 10-year median of 4.58. GuruFocus rates CHIX:GETIBS with a GF Score™ of 73/100 and a GF Value™ of kr192.70 (Modestly Overvalued). The stock has 10 warning signs investors should review. Among 323 Medical Devices & Instruments companies, Getinge AB ranks better than 77.4% on this metric.
Getinge AB's yield on cost for the quarter that ended in Jun. 2026 was 5.45.
The historical rank and industry rank for Getinge AB's 5-Year Yield-on-Cost % or its related term are showing as below:
CHIX:GETIBs'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.22 Med: 4.58 Max: 7.23
Current: 5.45
During the past 13 years, Getinge AB's highest Yield on Cost was 7.23. The lowest was 1.22. And the median was 4.58.
CHIX:GETIBs's 5-Year Yield-on-Cost % is ranked better than 77.4% of 323
companies
in the Medical Devices & Instruments industry
Industry Median: 2.51
vs CHIX:GETIBs: 5.45
Getinge AB (CHIX:GETIBs) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Getinge AB 5-Year Yield-on-Cost % Related Terms
CHIX:GETIBS vs ABT, SYK, MDT: 5-Year Yield-on-Cost % Comparison
For the Medical Devices subindustry, Getinge AB's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Getinge AB 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Getinge AB's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Getinge AB's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Getinge AB is calculated as
Getinge AB (CHIX:GETIBS) has a 5-Year Yield-on-Cost % of 5.45 as of Jul. 27, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Getinge AB and its competitors. This is 19% above median its historical median of 4.58. Over the past decade, Getinge AB's 5-Year Yield-on-Cost % has ranged from 1.22 to 7.23. According to the industry distribution chart, Getinge AB ranks #73 out of 323 companies in the Medical Devices & Instruments industry, placing it in the top 22.6%.
Is Getinge AB's 5-Year Yield-on-Cost % too high?
Getinge AB's current 5-Year Yield-on-Cost % of 5.45 is 19% above median its 10-year median of 4.58. Over the past 10 years, this metric has ranged from a low of 1.22 to a high of 7.23. The Medical Devices & Instruments industry median 5-Year Yield-on-Cost % is 2.51. Getinge AB's value of 5.45 is 117.1% above this industry median. Based on the distribution chart, Getinge AB ranks #73 out of 323 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Getinge AB has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Getinge AB's 5-Year Yield-on-Cost % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Getinge AB ranks #73 out of 323 companies for 5-Year Yield-on-Cost %. This places Getinge AB in the top 23% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.51. Getinge AB's value of 5.45 is 117.1% above this benchmark. Historically, Getinge AB's own 5-Year Yield-on-Cost % has ranged from 1.22 to 7.23 over the past decade. While the company's 10-year median is 4.58 vs. the industry median of 2.51, Getinge AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.51, based on 323 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Getinge AB's current 5-Year Yield-on-Cost % of 5.45 is 117.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Getinge AB and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Getinge AB's current 5-Year Yield-on-Cost % is 5.45, which is 19% above median its own 10-year median of 4.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Getinge AB stock overvalued right now?
Based on GuruFocus' analysis, Getinge AB (CHIX:GETIBS) is currently considered Modestly Overvalued. The stock's GF Value™ is kr192.70, compared to a current price of kr231.00 — trading 19.9% above its estimated fair value. The current 5-Year Yield-on-Cost % is 5.45, which is 19% above median its 10-year median of 4.58 and 117.1% above the Medical Devices & Instruments industry median of 2.51. Getinge AB's overall GF Score™ is 73/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Getinge AB (CHIX:GETIBS), the current 5-Year Yield-on-Cost % is 5.45 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Getinge AB (CHIX:GETIBS) Overvalued in 2026?
Based on GuruFocus' analysis, Getinge AB stock appears to be overvalued.
The current stock price of kr231.00 is trading 19.9% above its estimated GF Value™ of kr192.70.
GuruFocus considers Getinge AB to be Modestly Overvalued.
Key valuation signals for CHIX:GETIBS:
5-Year Yield-on-Cost %: 5.45 (19% above median its 10-year median of 4.58)
GF Value™: kr192.70 vs. price of kr231.00 (19.9% above fair value)
Industry Position: 117.1% above the Medical Devices & Instruments median (#73 of 323)
No single metric tells the full story. See the CHIX:GETIBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Getinge, headquartered in Gothenburg, Sweden, manufactures a wide range of products for use in acute care, surgical, and life sciences in the hospital, pharmaceutical, and research settings. The company reports in three segments: acute care therapies (52% of revenue), surgical workflows (35%), and life sciences (13%). Product areas include ventilators, surgical stents, life support systems, sterilizers, surgical tables, and sterile transfer systems. Getinge derives revenue from a broad geographic footprint, with the Americas accounting for 45% of sales, Europe, Middle East, and Africa 35%, and Asia-Pacific the remaining 25%.
73GF Score
Get the complete analysis for CHIX:GETIBS
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:GETIBS has been successfully added to your 
